INAB

$1.91

Pre-MarketAs of Mar 17, 8:00 PM UTC

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.

Recent News

No recent news found.